A Randomized, Multi-Dose, Open-Label, Phase II Study of BMS-663513 as a Second-Line Monotherapy in Subjects With Previously Treated Unresectable Stage III or IV Melanoma
Interventional
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Radiographic imaging, photographic and clinical evaluation will be used for tumor assessment to determine 6-month progression-free survival rate
every 6 weeks starting at week 12 after randomization
No
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
United States: Food and Drug Administration
CA186-006
NCT00612664
March 2008
October 2009
Name | Location |
---|---|
Indiana University Melvin and Bren Simon Cancer Center | Indianapolis, Indiana 46202-5289 |
Providence Portland Medical Center | Portland, Oregon 97213-3635 |
The Angeles Clinic & Research Institute | Los Angeles, California 90404 |
Oncology Specialists, S.C. | Park Ridge, Illinois 60068 |
Yale University School Of Medicine | New Haven, Connecticut 06520 |
University of Texas | Houston, Texas 77225 |
Harry & Jeanette Weinberg Cancer Inst At Franklin Square | Baltimore, Maryland 21237 |
Dana-Farber Cancer Inst | Boston, Massachusetts 02115 |
Mem Sloan-Ket Can Ctr | New York, New York 10021 |
Blumenthal Cancer Center, Carolinas Medical Center | Charlotte, North Carolina 28204 |